Introduction
============

Chronic kidney disease (CKD) is a frequent comorbidity among patients with symptomatic cerebrovascular disease,^[@b1]^ which has been independently linked with poorer prognoses among stroke patients including greater short‐ and long‐term risk of death.^[@b2]--[@b6]^ Because most patients with CKD die of vascular causes, not progression to end‐stage renal disease, more precise quantification of the co‐morbid presence and effects of CKD among patients hospitalized with acute vascular events may be insightful.^[@b1]^ Moreover, it is conceivable that optimal evidence‐based treatment of hospitalized patients with both symptomatic vascular disease and CKD may improve clinical outcomes.^[@b1]^ Recognizing this, the American Heart Association issued an expert advisory recommending that healthcare providers aggressively manage their vascular disease patients with CKD in order to sever potential causal pathways between the kidney and the heart.^[@b7]^ However, little if anything is known about the quality of evidence‐based care provided to hospitalized stroke patients with CKD, and whether such care may differ by level of kidney dysfunction.

The objective of this study was 3‐fold: (1) properly quantify the prevalence of CKD among hospitalized ischemic stroke patients and its association with in‐hospital outcomes; (2) compare the quality of stroke‐related care (ie, interventions addressing the management of stroke) among ischemic stroke patients with and without CKD; (3) assess whether care quality and in‐hospital outcomes vary among ischemic stroke patients by CKD stage.

Methods
=======

Patient Population
------------------

We used data from the Get With The Guidelines‐Stroke (GWTG‐Stroke) program database. Details of the design and conduct of the program have been previously described.^[@b8]^ Briefly, the program is a voluntary, national, quality‐improvement initiative sponsored by the American Heart Association and American Stroke Association, geared at fostering improved adherence to guideline‐based care in patients hospitalized with stroke and TIA. Briefly, participating hospitals use an Internet‐based Patient Management Tool (Outcome Sciences Inc, a Quintiles Company) to enter data, receive decision support, and obtain feedback through on‐demand reports of performance on quality measures. GWTG‐Stroke participating hospitals record data from consecutive stroke and TIA hospital admissions. Case ascertainment is done via clinical identification during the hospital encounter, retrospective surveillance of International Classification of Diseases, ninth Revision codes, or both. Trained hospital personnel extract data on demographics, medical history, neuroimaging, in‐hospital treatment, and discharge characteristics. While the GWTG‐Stroke program is overrepresented with larger academic teaching hospitals, the patient demographics and comorbidites are similar to those described in other stroke registries and administrative databases.^[@b8]^ Outcome Sciences serves as the data collection and coordination center for GWTG. The Duke Clinical Research Institute serves as the data analysis center and has an agreement to analyze the aggregate de‐identified data for research purposes. Each participating hospital received either human research approval to enroll cases without individual patient consent under the common rule or a waiver of authorization and exemption from subsequent review by their Institutional Review Board.

Performance Measures
--------------------

Seven performance measures, pre‐selected by the GWTG‐Stroke program as primary targets for stroke quality‐improvement efforts based on prevailing expert consensus treatment guidelines,^[@b9]--[@b10]^ were used to compare the quality of stroke‐related care between ischemic stroke admissions with and without CKD. Acute ischemic stroke performance measures were: (1) intravenous tissue plasminogen activator in patients who arrive \<2 hours after symptom onset and with no contraindications to treatment; (2) antithrombotic medication (includes any aspirin, aspirin/dipyridamole, ticlopidine, clopidogrel, unfractionated heparin, low‐molecular‐weight heparin, and warfarin) administered within 48 hours of admission; and (3) deep vein thrombosis prophylaxis (includes heparins, heparinoids, other anticoagulants, or pneumatic compression devices) within 48 hours of admission in non‐ambulatory patients. Discharge ischemic stroke performance measures were: (1) antithrombotic (includes any aspirin, aspirin/dipyridamole, ticlopidine, clopidogrel, unfractionated heparin, low‐molecular‐weight heparin, and warfarin) medication; (2) anticoagulation (includes therapeutic doses of warfarin, heparinoid), or other anticoagulants such as direct thrombin inhibitors) for patients with a diagnosis of atrial fibrillation or flutter (paroxysmal, persistent, or permanent); (3) cholesterol treatment (includes statins, fibrates niacin, binding resins, or selective cholesterol absorption inhibitors) if low‐density lipoprotein cholesterol (LDL‐C) \>100 mg/dL or if LDL‐C is not documented; and (4) counseling or medication for smoking cessation for patients who are current smokers (any cigarettes in past year; "smoking cessation"). The GTWG‐Stroke assessment tool allows clinicians to check a box indicating a contraindication to a given performance measure and in such cases, compliance with the performance measure is seen as being met. To summarize the overall quality of stroke‐related care, we calculated a defect‐free measure of care, which is a binary variable calculated as the proportion of patients who received all of the interventions for which they were eligible.

CKD Definitions
---------------

The serum creatinine level obtained at the time of hospital admission was used to determine the estimated glomerular filtration rate. Estimated glomerular filtration rate per the Modification of Diet in Renal Disease Study Group equation was calculated for each patient using the abbreviated Modification of Diet in Renal Disease formula: estimated GFR (mL/min per 1.73 m^2^)=186×\[serum creatinine\]−1.15×age−0.203×\[0.742 if female\]×\[1.21 if black\].^[@b11]^ CKD was defined as eGFR\<60 mL/min per 1.73 m^2^. GWTG‐Stroke patients without CKD (controls) were the referent group for purposes of comparison. We then categorized patients by kidney function (GFR in mL/min per 1.73 m^2^) using modified definitions from the National Kidney Foundation---Kidney Disease Outcomes Quality Initiative clinical practice guidelines: normal (GFR≥90), mild (60≤GFR\<90), moderate (30≤GFR\<60), severe (15≤GFR\<30), and kidney failure (GFR\<15).

Statistical Analysis
--------------------

Patient demographic and clinical variables, hospital‐level characteristics, and compliance with the individual and summary quality‐of‐care measures were compared between patients with and without CKD. Percentages and means±SD were reported for categorical and continuous variables, respectively. Pearson χ^2^ test and Wilcoxon rank‐sum tests were used to compare the categorical and continuous variables, respectively, between patients with and without CKD. To compare variables among CKD stages we used Pearson χ^2^ test and Kruskal Wallis tests, respectively. The relationship between CKD status (yes versus no) and different levels of renal function versus compliance with individual performance measures, as well as the defect‐free summary measure of care were further examined using multivariable logistic regression models. To account for within‐hospital clustering, generalized estimating equations were used to generate unadjusted and adjusted models.^[@b12]^ Confidence intervals and *P* values were computed using Wald tests. The adjusted models included the following pre‐specified potential confounders: age, sex, race, medical history (including atrial fibrillation, prosthetic heart valve, previous stroke/TIA, coronary heart disease, or previous myocardial infarction \[coronary artery disease/previous MI\], carotid stenosis, peripheral vascular disease, hypertension, diabetes, dyslipidemia, heart failure, and current smoking), systolic blood pressure (SBP) at admission, hospital size, region, teaching status, primary stroke center status and the number of annual stroke discharges from each hospital. Missing values for medical history (0.22%) were imputed to no history and for SBP (2.62%) to the median value. Patients with missing information in 1 or more hospitals characteristics were excluded from the models (less than 0.25%).

Similar multivariable logistic regression analyses were performed to explore the relationship between CKD status and 2 other binary outcome measures (ie, in‐hospital mortality and discharge status \[home versus other\]). We included the same set of pre‐specified potential confounders in all 3 of these outcomes‐based models, and we chose not to adjust for differences in performance measures because of the inherent problem of confounding by indication (ie, the tendency for patients with inherently poorer prognosis to receive less care). Only eligible patients for each outcome with complete data are included in each model. We also conducted sensitivity analyses by generating models that included all of the aforementioned variables and the measure of stroke severity (NIH Stroke Scale Score) in the subgroup of patients in which this measure of stroke severity was documented (NIHSS missing in 36.1% of study population). NIHSS was analyzed as a continuous variable. All tests are 2‐tailed with *P*\<0.05 considered as the level of statistical significance. All statistical analyses were performed using SAS software (version X SAS Institute Inc).

Results
=======

Of 858 124 ischemic stroke admissions at 1624 hospitals during the study period, after excluding patients with serum creatinine values missing (n=151 634), reported serum creatinine value out of range (ie, 0 or \>20 mg/dL, n=2195), sex or race variable missing (n=979), and patient transferred out/left against medical advice/discharge status missing/(n=23 489), there were 679 827 ischemic stroke admissions. An analysis of just those patients with serum creatinine values available versus missing revealed generally similar demographic and clinical characteristics, and where differences existed they were small and unlikely to be of major relevance ([Table 1](#tbl01){ref-type="table"}).

###### 

Baseline Demographic and Clinical Characteristics by Missing Serum Creatinine Variable Status

  Variable                                          Description     Overall (N=826 828)   Serum Creatinine Not Missing (N=679 827)   Serum Creatinine Missing (N=147 001)   *P* Value                     
  ------------------------------------------------- --------------- --------------------- ------------------------------------------ -------------------------------------- ----------- --------- ------- ----------
  *Demographics*                                                                                                                                                                                          
  Age (18 to 110), y                                Mean                                  70.85                                                                             70.83                 70.91   0.1069
  Standard deviation                                                14.62                                                            14.63                                              14.61             
  Minimum                                                           18.00                                                            18.00                                              18.00             
  Maximum                                                           110.00                                                           110.00                                             110.00            
  Sex                                               Female          42 8519               51.83                                      352 967                                51.92       75 552    51.40   0.0003
  Race/ethnicity                                    White (n, %)    584 486               70.69                                      480 323                                70.65       104 163   70.86   \<0.0001
  Black (n, %)                                      134 936         16.32                 114 281                                    16.81                                  20 655      14.05             
  Hispanic (n, %)                                   53 998          6.53                  44 306                                     6.52                                   9692        6.59              
  *Medical history*                                                                                                                                                                                       
  Atrial fibrillation/flutter                       Yes (n, %)      148 626               18.10                                      121 918                                17.97       26 708    18.71   \<0.0001
  Coronary artery disease                           Yes (n, %)      211 217               25.73                                      175 430                                25.86       35 787    25.07   \<0.0001
  Carotid stenosis                                  Yes (n, %)      32 417                3.95                                       26 454                                 3.90        5963      4.18    \<0.0001
  Diabetes mellitus                                 Yes (n, %)      266 500               32.46                                      221 128                                32.60       45 372    31.79   \<0.0001
  Dyslipidemia                                      Yes (n, %)      351 473               42.81                                      289 409                                42.67       62 064    43.48   \<0.0001
  Hypertension                                      Yes (n, %)      624 904               76.11                                      518 145                                76.39       106 759   74.80   \<0.0001
  Prosthetic heart valve                            Yes (n, %)      10 893                1.33                                       8994                                   1.33        1899      1.33    0.8920
  Peripheral vascular disease                       Yes (n, %)      38 970                4.75                                       32 013                                 4.72        6957      4.87    0.0125
  Heart failure                                     Yes (n, %)      71 959                8.76                                       59 341                                 8.75        12 618    8.84    0.2639
  Smoker                                            Yes (n, %)      150 389               18.32                                      124 675                                18.38       25 714    18.02   0.0012
  Previous stroke/transient ischemic attack         Yes (n, %)      254 577               31.01                                      211 268                                31.15       43 309    30.34   \<0.0001
  *Evaluation*                                                                                                                                                                                            
  National Institute of Health Stroke Scale score   0 to 9 (n, %)   385 778               46.66                                      316 733                                46.59       69 045    46.97   \<0.0001
  Door to CT scan ≤25 minutes                       Yes (n, %)      154 917               18.74                                      128 019                                18.83       26 898    18.30   0.0081
  *Pre‐admission drugs*                                                                                                                                                                                   
  Anticoagulants                                    Yes (n, %)      84 706                10.24                                      75 744                                 11.14       8962      6.10    0.7098
  Antiplatelets                                     Yes (n, %)      347 104               41.98                                      310 558                                45.68       36 546    24.86   0.0216
  Anti‐hypertensives                                Yes (n, %)      525 329               63.54                                      477 350                                70.22       47 979    32.64   \<0.0001
  Cholesterol reducers                              Yes (n, %)      346 488               41.91                                      284 590                                41.86       61 898    42.11   \<0.0001
  Anti‐diabetics                                    Yes (n, %)      192 618               23.30                                      175 644                                25.84       16 974    11.55   \<0.0001

CT indicates computed tomography.

Among these ischemic stroke admissions (n=679 827), over one‐third (34.8%; n=236 662) met the definition of CKD. Patients with CKD were older (mean, 76.2 versus 68 years), more likely to be female or white, and more likely to have a medical history of stroke/TIA, carotid stenosis, coronary artery disease/previous MI, hypertension, dyslipidemia, diabetes, atrial fibrillation/flutter, peripheral arterial disease, and heart failure, but they were less likely to be current smokers. Patients with CKD had more severe strokes (mean NIH stroke scale score 8.0 versus 6.7). [Table 2](#tbl02){ref-type="table"} compares the demographic and clinical characteristics of ischemic stroke patients by presence of CKD and stage of kidney dysfunction. Compared with patients with earlier stages of kidney dysfunction (mild or moderate), those with more advanced stages of dysfunction (severe or failure) were older, more likely to be of black race, and much more likely to have a medical history of diabetes, peripheral arterial disease, and heart failure, but less likely to be of independent ambulatory status prior to admission. Patients with more advanced stages of kidney dysfunction (versus earlier stages) were more likely to present with altered level of consciousness or lower admission systolic blood pressure levels, but less likely to have strokes of mild severity.

###### 

Baseline Patient Characteristics by Chronic Kidney Disease Stage

  Variable                                    Description           No CKD (GFR≥90) (N=163 772)   Mild CKD (60≤GFR\<90) (N=279 393)   Moderate CKD (30≤GFR\<60) (N=194 030)   Severe CKD (15≤GFR\<30) (N=285 83)   Renal Failure (GFR\<15) (N=14 049)   *P* Value                                                            
  ------------------------------------------- --------------------- ----------------------------- ----------------------------------- --------------------------------------- ------------------------------------ ------------------------------------ ---------------- -------- ---------------- -------- ---------------- ----------
  *Demographics*                                                                                                                                                                                                                                                                                                             
  Age (18 to 110), y                          Mean                                                62.21 (14.9)                                                                71.39 (13.8)                                                              76.81 (12.1)              75.64 (13.3)              68.10 (13.6)     
  Sex                                         Female                70 029                        42.76                               13 8667                                 49.63                                11 8221                              60.93            17 898   62.62            8152     58.03            \<0.0001
  Ethnicity/race                              White                 10 1145                       61.76                               20 3409                                 72.80                                14 8431                              76.50            20 043   70.12            7295     51.93            \<0.0001
  Black                                       38 863                23.73                         42 165                              15.09                                   23 851                               12.29                                5004             17.51    4398             31.30                     
  Hispanic                                    13 043                7.96                          16 848                              6.03                                    11 041                               5.69                                 1958             6.85     1416             10.08                     
  *Arrival*                                                                                                                                                                                                                                                                                                                  
  EMS arrival                                 EMS from home/scene   69 622                        42.51                               13 7306                                 49.14                                11 0803                              57.11            17 460   61.09            7971     56.74            \<0.0001
  Last known well to arrival, minutes         Mean                                                603.01 (988)                                                                510.11 (880.1)                                                            469.08 (836.8)            498.07 (900.5)            570.06 (956.9)   
  *Past medical history*                                                                                                                                                                                                                                                                                                     
  Atrial fib/flutter                          Yes                   17 083                        10.46                               50 154                                  17.99                                46 136                               23.83            6314     22.12            2231     15.91            \<0.0001
  CAD/prior MI                                Yes                   29 045                        17.78                               68 260                                  24.49                                62 387                               32.22            10 698   37.48            5040     35.93            \<0.0001
  Carotid stenosis                            Yes                   4214                          2.58                                10 111                                  3.63                                 9911                                 5.12             1611     5.64             607      4.33             \<0.0001
  Diabetes mellitus                           Yes                   49 130                        30.08                               79 730                                  28.60                                69 824                               36.06            14 195   49.74            8249     58.81            \<0.0001
  Dyslipidemia                                Yes                   58 684                        35.93                               11 9513                                 42.87                                91 530                               47.27            13 576   47.57            6106     43.53            \<0.0001
  Hypertension                                Yes                   109 599                       67.10                               209 554                                 75.17                                162 084                              83.72            24 782   86.83            12 126   86.45            \<0.0001
  Prosthetic heart valve                      Yes                   1599                          0.98                                3622                                    1.30                                 3119                                 1.61             452      1.58             202      1.44             \<0.0001
  PVD                                         Yes                   5165                          3.16                                11 275                                  4.04                                 11 591                               5.99             2539     8.90             1443     10.29            \<0.0001
  Heart failure                               Yes                   7210                          4.41                                19 347                                  6.94                                 24 612                               12.71            5583     19.56            2589     18.46            \<0.0001
  Smoker                                      Yes                   48 775                        29.86                               48 747                                  17.49                                22 166                               11.45            3199     11.21            1788     12.75            \<0.0001
  Previous stroke/TIA                         Yes                   42 403                        25.96                               83 887                                  30.09                                68 990                               35.63            10 848   38.01            5140     36.65            \<0.0001
  *Premorbid medications*                                                                                                                                                                                                                                                                                                    
  Anticoagulants                              Yes                   13 432                        8.20                                30 912                                  11.06                                26 062                               13.43            3695     12.93            1643     11.69            \<0.0001
  Antiplatelets                               Yes                   59 729                        36.47                               12 6970                                 45.44                                101 163                              52.14            15 393   53.85            7303     51.98            \<0.0001
  Anti‐Hypertensives                          Yes                   91 530                        55.89                               190 835                                 68.30                                158 375                              81.62            24 864   86.99            11 746   83.61            \<0.0001
  Antilipemics                                Yes                   53 597                        32.73                               11 4952                                 41.14                                94 150                               48.52            14 793   51.75            7098     50.52            
  Anti‐diabetics                              Yes                   38 011                        23.21                               63 481                                  22.72                                56 663                               29.20            11 321   39.61            6168     43.90            \<0.0001
  *Pre‐morbid status*                                                                                                                                                                                                                                                                                                        
  Ambulation                                  Independent           136 608                       83.41                               229 396                                 82.11                                150 581                              77.61            20 245   70.83            9764     69.50            \<0.0001
  *Symptom type and severity*                                                                                                                                                                                                                                                                                                
  Altered Consciousness                       Yes                   24 012                        14.66                               47 998                                  17.18                                42 633                               21.97            7913     27.68            3879     27.61            \<0.0001
  NIHSS levels                                0‐9                   80 491                        49.15                               134 831                                 48.26                                85 084                               43.85            11 028   38.58            5299     37.72            
  *Admission care process*                                                                                                                                                                                                                                                                                                   
  Door to CT≤25 minutes                       Yes                   26 861                        16.40                               54 149                                  19.38                                39 757                               20.49            5225     18.28            2027     14.43            \<0.0001
  *Admission biomarkers*                                                                                                                                                                                                                                                                                                     
  Body mass index, kg/m^2^                    Mean                                                28.47 (7.8)                                                                 28.04 (7.2)                                                               27.89 (7.2)               28.08 (7.6)               28.13 (8.0)      
  Systolic blood pressure (50 to 250 mm Hg)   Mean                                                156.05 (29.2)                                                               158.36 (29.3)                                                             156.45 (30.9)             151.17 (34.2)             151.66 (35.4)    \<0.0001
  Serum Creatinine (0 to 20 mg/dL)            Mean                                                0.72 (0.2)                                                                  0.96 (0.2)                                                                1.38 (0.3)                2.56 (0.6)                6.55 (2.7)       
  Hospital characteristics                                                                                                                                                                                                                                                                                                   
  Number of beds                              Mean                                                471.47 (309.4)                                                              439.62 (297.0)                                                            423.15 (290.2)            428.58 (296)              452.77 (296.1)   \<0.0001
  Region                                      West                  27 871                        17.02                               48 663                                  17.42                                32 257                               16.62            4541     15.89            2444     17.40            \<0.0001
  South                                       59 701                36.45                         99 676                              35.68                                   70 335                               36.25                                10 764           37.66    5618             39.99                     
  Midwest                                     33 084                20.20                         56 647                              20.28                                   40 035                               20.63                                5849             20.46    2736             19.47                     
  Northeast                                   43 116                26.33                         74 407                              26.63                                   51 403                               26.49                                7429             25.99    3251             23.14                     
  Hospital type                               Academic              107 151                       65.43                               165 986                                 59.41                                109 036                              56.20            16 258   56.88            8448     60.13            \<0.0001
  Rural location                              Yes                   6041                          3.69                                11 169                                  4.00                                 8592                                 4.43             1316     4.60             475      3.38             \<0.0001
  Avg. annual ischemic stroke cases           Mean                                                240.20 (146.3)                                                              229.79 (141.1)                                                            223.38 (139.4)            223.40 (140.7)            230.76 (141.7)   

CAD indicates coronary artery disease; CKD, chronic kidney disease; CT, computed tomography; GFR, glomerular filtration rate; MI, myocardial infarction; PVD, peripheral vascular disease; TIA, transient ischemic attack.

There were significantly higher rates of compliance with all 7 performance measures and defect‐free care among those without CKD compared with those with CKD. However, for some of the measures these differences were numerically rather modest. In‐hospital outcomes were much worse for those with CKD versus without CKD across all 3 endpoints studied including in‐hospital case fatality ([Table 3](#tbl03){ref-type="table"}). [Table 4](#tbl04){ref-type="table"} shows a comparison of frequencies among ischemic stroke patients with various stages of kidney dysfunction. Significantly lower rates of compliance were observed with all 7 performance measures and defect‐free care among those patients with more advanced stages of kidney dysfunction (versus earlier stages), but these differences were numerically very modest with the exception of patients presenting within 2 hours of ictus receiving IV tPA, for which there was a lower compliance rate ranging from 4 to 10 percentage points in those in advanced versus earlier stages of dysfunction ([Table 4](#tbl04){ref-type="table"}). In‐hospital outcomes were much worse for advanced versus earlier stages of renal dysfunction including in‐hospital case fatality ([Table 4](#tbl04){ref-type="table"}).

###### 

Frequencies Comparing Ischemic Stroke Patients With Chronic Kidney Disease (CKD) to Those Without CKD for 7 Performance Measures, a Summary Defect‐Free Care Measure, and In‐Hospital Outcomes

  Variable                                                     Overall (N=679 827)   No CKD (GFR≥60) (N=443 165)   CKD (GFR\<60) (N=236 662)   *P* Value                     
  ------------------------------------------------------------ --------------------- ----------------------------- --------------------------- ----------- --------- ------- ----------
  Performance measures                                         n                     \%                            n                           \%          n         \%      
  Patients presenting within 2 hours of ictus receive IV tPA   35 330                78.03                         23 039                      78.55       12 291    77.08   0.0003
  Antithrombotic prescribed within 48 hours of admission       414 672               96.85                         263 202                     97.12       151 470   96.39   \<0.0001
  Deep venous thrombosis prophylaxis                           322 251               97.50                         211 230                     97.59       111 021   97.34   \<0.0001
  Antithrombotic prescribed at discharge                       583 330               98.60                         390 884                     98.66       192 446   98.49   \<0.0001
  Anticoagulation prescribed at discharge for AF patients      86 199                94.61                         51 070                      95.05       35 129    93.98   \<0.0001
  Smoking cessation intervention provided at discharge         112 020               97.12                         88 739                      97.32       23 281    96.35   \<0.0001
  Lipid‐lowering agent prescribed at discharge                 315 999               94.40                         209 787                     94.60       106 212   94.02   \<0.0001
  Composite measure                                                                                                                                                          
  Defect‐free: compliance 100%                                 590 005               90.81                         390 431                     91.27       199 574   89.93   \<0.0001
  In‐hospital outcomes                                                                                                                                                       
  In‐hospital case fatality                                    32 290                4.75                          16 786                      3.79        15 504    6.55    \<0.0001
  In‐hospital case fatality or discharged to hospice           61 687                9.07                          31 580                      7.13        30 107    12.72   \<0.0001
  Discharge destination other than directly home               314 765               8.61                          190 252                     44.62       124 513   56.30   \<0.0001

AF indicates atrial fibrillation; GFR, glomerular filtration rate.

###### 

Frequencies Comparing Ischemic Stroke Patients With Various Categories of Chronic Kidney Disease (CKD) to Those Without CKD for 7 Performance Measures, a Summary Defect‐Free Care Measure, and In‐Hospital Outcomes

  Variable                                                     No CKD (GFR≥90) (N=163 772)   Mild CKD (60≤GFR\<90) (N=279 393)   Moderate CKD (30≤GFR\<60) (N=194 030)   Severe CKD (15≤GFR\<30) (N=28 583)   Renal Failure (GFR\<15) (N=14 049)   *P* Value                                     
  ------------------------------------------------------------ ----------------------------- ----------------------------------- --------------------------------------- ------------------------------------ ------------------------------------ ----------- -------- ------- -------- ------- ----------
  Performance measures                                         n                             \%                                  n                                       \%                                   n                                    \%          n        \%      n        \%      
  Patients presenting within 2 hours of ictus receive IV tPA   7480                          78.21                               15 559                                  78.72                                10 678                               77.98       1185     73.06   428      67.94   0.0002
  Antithrombotic prescribed within 48 hours of admission       96 901                        96.97                               166 301                                 97.21                                122 656                              96.75       19 097   95.22   9717     94.21   \<0.0001
  Deep venous thrombosis prophylaxis                           80 105                        97.62                               131 125                                 97.57                                91 000                               97.40       13 375   97.17   6646     96.82   \<0.0001
  Antithrombotic prescribed at discharge                       146 502                       98.55                               244 382                                 98.73                                159 897                              98.62       21 645   97.92   10 904   97.78   0.0004
  Anticoagulation prescribed at discharge for AF patients      13 457                        94.78                               37 613                                  95.15                                30 423                               94.36       3432     91.74   1274     91.20   \<0.0001
  Smoking cessation intervention provided at discharge         44 581                        97.47                               44 158                                  97.17                                19 178                               96.53       2629     95.81   1474     95.04   \<0.0001
  Lipid‐lowering agent prescribed at discharge                 76 542                        94.74                               133 245                                 94.51                                88 724                               94.11       11 998   93.57   5490     93.51   \<0.0001
  Composite measure                                                                                                                                                                                                                                                                              
  Defect‐free: compliance 100%                                 145 339                       91.37                               245 092                                 91.21                                164 938                              90.31       23 136   88.42   11 500   87.61   \<0.0001
  In‐hospital outcomes                                                                                                                                                                                                                                                                           
  In‐hospital case fatality                                    5551                          3.39                                11 235                                  4.02                                 11 451                               5.90        2775     9.71    1278     9.10    \<0.0001
  In‐hospital case fatality or discharged to hospice           9842                          6.01                                21 738                                  7.78                                 23 035                               11.87       4950     17.32   2122     15.10   \<0.0001
  Discharge destination other than directly home               65 560                        41.44                               12 4692                                 46.50                                101 764                              55.74       15 811   61.26   6938     54.33   \<0.0001

AF indicates atrial fibrillation; GFR, glomerular filtration rate.

[Table 5](#tbl05){ref-type="table"} displays unadjusted and adjusted odds ratios comparing ischemic stroke patients with various stages of kidney disease to those with normal renal function for the pre‐specified stroke hospitalization performance measures and the summary defect‐free care measure. Compared with patients with normal kidney function, those with CKD were significantly less likely to receive smoking cessation counseling at discharge (adjusted OR 0.86, 95% CI: 0.80 to 0.93), antithrombotic prescribed within 48 hours of admission (adjusted OR 0.82, 95% CI: 0.79 to 0.85), antithrombotic at discharge (adjusted OR 0.87, 95% CI: 0.83 to 0.91), anticoagulation at discharge if there was a diagnosis of atrial fibrillation or atrial flutter (adjusted OR 0.90, 95% CI: 0.85 to 0.95), lipid modifier at discharge (adjusted OR 0.96, 95% CI: 0.93 to 0.99), and defect‐free care (adjusted OR 0.91, 95% CI: 0.89 to 0.92).

###### 

Unadjusted and Adjusted Odds Ratios Comparing Ischemic Stroke Patients With Various Stages of Kidney Dysfunction to Those With Normal Kidney Function for 7 Performance Measures and a Summary Defect‐Free Care Measure

  Process Measures                                                Category of CKD                                 Unadjusted OR (95% CI)[\*](#tf5-1){ref-type="table-fn"}   *P* Value   Adjusted OR (95% CI)[\*](#tf5-1){ref-type="table-fn"}   *P* Value
  --------------------------------------------------------------- ----------------------------------------------- --------------------------------------------------------- ----------- ------------------------------------------------------- -----------
  Patients presenting within 2 hours of ictus receive IV tPA      CKD (GFR\<60)                                   0.96 (0.93 to 0.99)                                       0.0158      0.96 (0.91 to 1.01)                                     0.0903
  Patients presenting within 2 hours of ictus receive IV tPA      Mild kidney dysfunction (GFR ≥60 to \<90)       1.04 (1.00 to 1.08)                                       0.0571      1.06 (1.00 to 1.12)                                     0.0585
  Patients presenting within 2 hours of ictus receive IV tPA      Moderate kidney dysfunction (GFR ≥30 to \<60)   1.02 (0.97 to 1.07)                                       0.4550      1.04 (0.97 to 1.11)                                     0.3105
  Patients presenting within 2 hours of ictus receive IV tPA      Severe kidney dysfunction (GFR ≥15 to \<30)     0.86 (0.79 to 0.93)                                       0.0004      0.85 (0.76 to 0.96)                                     0.0088
  Patients presenting within 2 hours of ictus receive IV tPA      Renal failure (GFR\<15)                         0.74 (0.65 to 0.84)                                       \<0.0001    0.72 (0.61 to 0.85)                                     0.0001
  Deep venous thrombosis prophylaxis                              CKD (GFR\<60)                                   0.93 (0.89 to 0.97)                                       0.0003      0.96 (0.91 to 1.00)                                     0.0619
  Deep venous thrombosis prophylaxis                              Mild kidney dysfunction (GFR ≥60 to \<90)       1.00 (0.95 to 1.05)                                       0.9602      1.02 (0.96 to 1.07)                                     0.6040
  Deep venous thrombosis prophylaxis                              Moderate kidney dysfunction (GFR ≥30 to \<60)   0.95 (0.90 to 1.00)                                       0.0480      0.98 (0.93 to 1.05)                                     0.6012
  Deep venous thrombosis prophylaxis                              Severe kidney dysfunction (GFR ≥15 to \<30)     0.89 (0.80 to 0.98)                                       0.0146      0.94 (0.84 to 1.05)                                     0.2477
  Deep venous thrombosis prophylaxis                              Renal failure (GFR\<15)                         0.79 (0.70 to 0.90)                                       0.0003      0.83 (0.72 to 0.95)                                     0.0068
  Smoking cessation intervention provided at discharge            CKD (GFR\<60)                                   0.77 (0.73 to 0.82)                                       \<0.0001    0.86 (0.80 to 0.93)                                     0.0001
  Smoking cessation intervention provided at discharge            Mild kidney dysfunction (GFR ≥60 to \<90)       0.89 (0.85 to 0.94)                                       \<0.0001    0.95 (0.88 to 1.02)                                     0.1604
  Smoking cessation intervention provided at discharge            Moderate kidney dysfunction (GFR ≥30 to \<60)   0.76 (0.71 to 0.81)                                       \<0.0001    0.87 (0.80 to 0.96)                                     0.0034
  Smoking cessation intervention provided at discharge            Severe kidney dysfunction (GFR ≥15 to \<30)     0.66 (0.58 to 0.74)                                       \<0.0001    0.76 (0.65 to 0.89)                                     0.0009
  Smoking cessation intervention provided at discharge            Renal failure (GFR\<15)                         0.59 (0.48 to 0.71)                                       \<0.0001    0.62 (0.48 to 0.78)                                     0.0001
  Antithrombotic prescribed within 48 hours of admission          CKD (GFR\<60)                                   0.80 (0.78 to 0.83)                                       \<0.0001    0.82 (0.79 to 0.85)                                     \<0.0001
  Antithrombotic prescribed within 48 hours of admission          Mild kidney dysfunction (GFR ≥60 to \<90)       1.05 (1.01 to 1.10)                                       0.0075      1.08 (1.03 to 1.13)                                     0.0011
  Antithrombotic prescribed within 48 hours of admission          Moderate kidney dysfunction (GFR ≥30 to \<60)   0.91 (0.88 to 0.95)                                       \<0.0001    0.96 (0.91 to 1.01)                                     0.1164
  Antithrombotic prescribed within 48 hours of admission          Severe kidney dysfunction (GFR ≥15 to \<30)     0.64 (0.60 to 0.69)                                       \<0.0001    0.67 (0.62 to 0.73)                                     \<0.0001
  Antithrombotic prescribed within 48 hours of admission          Renal Failure (GFR\<15)                         0.54 (0.49 to 0.58)                                       \<0.0001    0.54 (0.49 to 0.59)                                     \<0.0001
  Antithrombotic prescribed at discharge                          CKD (GFR\<60)                                   0.92 (0.89 to 0.95)                                       \<0.0001    0.87 (0.83 to 0.91)                                     \<0.0001
  Antithrombotic prescribed at discharge                          Mild kidney dysfunction (GFR ≥60 to \<90)       1.12 (1.07 to 1.17)                                       \<0.0001    1.08 (1.01 to 1.14)                                     0.0055
  Antithrombotic prescribed at discharge                          Moderate kidney dysfunction (GFR ≥30 to \<60)   1.06 (1.01 to 1.11)                                       0.0122      0.98 (0.92 to 1.05)                                     0.5877
  Antithrombotic prescribed at discharge                          Severe kidney dysfunction (GFR ≥15 to \<30)     0.76 (0.70 to 0.82)                                       \<0.0001    0.68 (0.61 to 0.76)                                     \<0.0001
  Antithrombotic prescribed at discharge                          Renal Failure (GFR\<15)                         0.72 (0.65 to 0.81)                                       \<0.0001    0.68 (0.59 to 0.78)                                     \<0.0001
  Anticoagulation prescribed at discharge for AF patients         CKD (GFR\<60)                                   0.85 (0.81 to 0.89)                                       \<0.0001    0.90 (0.85 to 0.95)                                     0.0001
  Anticoagulation prescribed at discharge for AF patients         Mild kidney dysfunction (GFR ≥60 to \<90)       1.07 (1.01 to 1.14)                                       0.0222      1.18 (1.09 to 1.27)                                     \<0.0001
  Anticoagulation prescribed at discharge for AF patients         Moderate kidney dysfunction (GFR ≥30 to \<60)   0.95 (0.89 to 1.01)                                       0.0908      1.08 (0.99 to 1.18)                                     0.0737
  Anticoagulation prescribed at discharge for AF patients         Severe kidney dysfunction (GFR ≥15 to \<30)     0.68 (0.61 to 0.76)                                       \<0.0001    0.76 (0.67 to 0.87)                                     0.0001
  Anticoagulation prescribed at discharge for AF patients         Renal Failure (GFR\<15)                         0.64 (0.55 to 0.75)                                       \<0.0001    0.64 (0.53 to 0.77)                                     \<0.0001
  Lipid‐lowering agent prescribed at discharge                    CKD (GFR\<60)                                   0.93 (0.91 to 0.95)                                       \<0.0001    0.96 (0.93 to 0.99)                                     0.0071
  Lipid‐lowering agent prescribed at discharge                    Mild kidney dysfunction (GFR ≥60 to \<90)       0.99 (0.96 to 1.02)                                       0.4052      1.03 (0.99 to 1.07)                                     0.1256
  Lipid‐lowering agent prescribed at discharge                    Moderate kidney dysfunction (GFR ≥30 to \<60)   0.94 (0.90 to 0.97)                                       0.0002      1.00 (0.96 to 1.05)                                     0.9794
  Lipid to lowering agent prescribed at discharge                 Severe kidney dysfunction (GFR ≥15 to \<30)     0.87 (0.81 to 0.93)                                       \<0.0001    0.90 (0.83 to 0.97)                                     0.0068
  Lipid‐lowering agent prescribed at discharge                    Renal Failure (GFR\<15)                         0.84 (0.77 to 0.92)                                       0.0001      0.83 (0.74 to 0.92)                                     0.0003
  Defect‐free: compliance 100%[\*](#tf5-2){ref-type="table-fn"}   CKD (GFR\<60)                                   0.89 (0.87 to 0.90)                                       \<0.0001    0.91 (0.89 to 0.92)                                     \<0.0001
  Defect‐free: compliance 100%                                    Mild kidney dysfunction (GFR ≥60 to \<90)       0.99 (0.97 to 1.01)                                       0.1954      1.00 (0.98 to 1.02)                                     0.8929
  Defect‐free: compliance 100%                                    Moderate kidney dysfunction (GFR ≥30 to \<60)   0.91 (0.89 to 0.93)                                       \<0.0001    0.94 (0.92 to 0.97)                                     \<0.0001
  Defect‐free: compliance 100%                                    Severe kidney dysfunction (GFR ≥15 to \<30)     0.78 (0.75 to 0.81)                                       \<0.0001    0.80 (0.77 to 0.84)                                     \<0.0001
  Defect‐free: compliance 100%                                    Renal Failure (GFR\<15)                         0.73 (0.70 to 0.76)                                       \<0.0001    0.72 (0.68 to 0.76)                                     \<0.0001

CAD indicates coronary artery disease; CKD, Chronic Kidney Disease; GFR, glomerular filtration rate; LDL, low‐density lipoprotein; MI, myocardial infarction.

Compared to normal defined as a glomerular filtration rate≥90. All models are adjusted for age, race, gender, medical history (atrial fibrillation, prosthetic heart valve, previous stroke/TIA, CAD/previous MI, carotid stenosis, peripheral vascular disease, hypertension, dyslipidemia, heart failure, and current smoking), systolic blood pressure (SBP) at admission, hospital size, region, teaching status, and the number of annual stroke discharges from each hospital. Eligible patients were defined as: (1) if LDL \>100 mg/dL; (2) if patient was using lipid‐lowering agent at admission; or (3) if LDL was not measured and there were no contraindications to lipid‐lowering medications.

Defect‐free care represents the proportion of subjects who received all of the measures that they were eligible for.

Analysis by stage of kidney dysfunction ([Table 5](#tbl05){ref-type="table"}), shows that compared with patients with normal kidney function, for patients presenting within 2 hours of stroke onset who received IV tPA or for lipid modifier medication prescribed at discharge, those with severe dysfunction or renal failure versus normal kidney function were less likely to be in compliance; for antithrombotic agents prescribed within 48 hours of admission or at discharge, as well as anticoagulation prescribed at discharge in patients with atrial fibrillation or atrial flutter, those with severe dysfunction and renal failure were less likely to be in compliance, but those with mild dysfunction were more likely to be in compliance; and for defect‐free care, those with moderate dysfunction, severe dysfunction, and renal failure were less likely to be in compliance.

[Table 6](#tbl06){ref-type="table"} shows unadjusted and adjusted odds ratios comparing ischemic stroke patients with various stages of kidney dysfunction to those with normal function for the 3 outcome measures. In‐hospital case fatality was higher for patients with CKD versus no CKD (adjusted OR 1.44, 95% CI: 1.40 to 1.47), and progressively rose with more severe renal dysfunction to the extent that patients with renal failure had well over twice the odds of dying in the hospital compared to those without CKD (adjusted OR 2.39, 95% CI: 2.22 to 2.57). Presence of CKD (versus no CKD) was also associated with poorer outcomes with regard to the endpoints of in‐hospital case fatality or discharged to hospice (adjusted OR 1.31, 95% CI: 1.28 to 1.33) and discharge destination other than directly home (adjusted OR 1.06, 95% CI: 1.04 to 1.07). However, analyses by stage of renal dysfunction showed that patients with earlier stages of dysfunction had better outcomes than those with normal function: patients with mild dysfunction had lower odds of experiencing in‐hospital case fatality or being discharged to hospice (adjusted OR 0.88, 95% CI: 0.85 to 0.91), and those with mild dysfunction (adjusted OR 0.81, 95% CI: 0.80 to 0.83) or moderate dysfunction (adjusted OR 0.88, 95% CI: 0.86 to 0.90) had lower odds of discharge destination other than home. The more advanced stages of renal dysfunction (severe and failure) were both associated with higher odds of experiencing in‐hospital case fatality/being discharged to hospice and a discharge destination other than home ([Table 6](#tbl06){ref-type="table"}). Regression models that included the measure of stroke severity (NIH Stroke Scale Score) showed a similar pattern of results (not shown).

###### 

Unadjusted and Adjusted Odds Ratios Comparing Ischemic Stroke Patients With Various Stages of Kidney Dysfunction to Those With Normal Kidney Function for 3 Outcome Measures

  Outcome Measures                                     Category of CKD                                 Unadjusted OR (95% CI)[\*](#tf6-1){ref-type="table-fn"}   *P* Value   Adjusted OR (95% CI)[\*](#tf6-1){ref-type="table-fn"}   *P* Value
  ---------------------------------------------------- ----------------------------------------------- --------------------------------------------------------- ----------- ------------------------------------------------------- -----------
  In‐hospital case fatality                            CKD (GFR\<60)                                   1.90 (1.85 to 1.95)                                       \<0.0001    1.44 (1.40 to 1.47)                                     \<0.0001
  In‐hospital case fatality                            Mild kidney dysfunction (GFR ≥60 to \<90)       1.28 (1.23 to 1.33)                                       \<0.0001    0.99 (0.95 to 1.03)                                     0.5626
  In‐hospital case fatality                            Moderate kidney dysfunction (GFR ≥30 to \<60)   1.99 (1.91 to 2.08)                                       \<0.0001    1.27 (1.22 to 1.32)                                     \<0.0001
  In‐hospital case fatality                            Severe kidney dysfunction (GFR ≥15 to \<30)     3.45 (3.27 to 3.65)                                       \<0.0001    2.14 (2.03 to 2.26)                                     \<0.0001
  In‐hospital case fatality                            Renal failure (GFR\<15)                         3.16 (2.94 to 3.41)                                       \<0.0001    2.39 (2.22 to 2.57)                                     \<0.0001
  In‐hospital case fatality or discharged to hospice   CKD (GFR\<60)                                   1.94 (1.91 to 1.98)                                       \<0.0001    1.31 (1.28 to 1.33)                                     \<0.0001
  In‐hospital case fatality or discharged to hospice   Mild kidney dysfunction (GFR ≥60 to \<90)       1.35 (1.31 to 1.38)                                       \<0.0001    0.88 (0.85 to 0.91)                                     \<0.0001
  In‐hospital case fatality or discharged to hospice   Moderate kidney dysfunction (GFR ≥30 to \<60)   2.19 (2.12 to 2.25)                                       \<0.0001    1.07 (1.04 to 1.11)                                     \<0.0001
  In‐hospital case fatality or discharged to hospice   Severe kidney dysfunction (GFR ≥15 to \<30)     3.43 (3.30 to 3.56)                                       \<0.0001    1.70 (1.63 to 1.78)                                     \<0.0001
  In‐hospital case fatality or discharged to hospice   Renal failure (GFR\<15)                         2.91 (2.75 to 3.09)                                       \<0.0001    2.09 (1.96 to 2.23)                                     \<0.0001
  Discharge destination other than directly home       CKD (GFR\<60)                                   1.60 (1.58 to 1.62)                                       \<0.0001    1.06 (1.04 to 1.07)                                     \<0.0001
  Discharge destination other than directly home       Mild kidney dysfunction (GFR ≥60 to \<90)       1.23 (1.21 to 1.25)                                       \<0.0001    0.81 (0.80 to 0.83)                                     \<0.0001
  Discharge destination other than directly home       Moderate kidney dysfunction (GFR ≥30 to \<60)   1.78 (1.74 to 1.82)                                       \<0.0001    0.88 (0.86 to 0.90)                                     \<0.0001
  Discharge destination other than directly home       Severe kidney dysfunction (GFR ≥15 to \<30)     2.24 (2.17 to 2.31)                                       \<0.0001    1.10 (1.07 to 1.14)                                     \<0.0001
  Discharge destination other than directly home       Renal failure (GFR\<15)                         1.68 (1.61 to 1.75)                                       \<0.0001    1.11 (1.06 to 1.16)                                     \<0.0001

CAD indicates coronary artery disease; CKD, chronic kidney disease; GFR, glomerular filtration rate; LDL, low‐density lipoprotein; MI, myocardial infarction.

Compared to normal defined as a glomerular filtration rate≥90. All models are adjusted for age, race, gender, medical history (atrial fibrillation, prosthetic heart valve, previous stroke/TIA, CAD/previous MI, carotid stenosis, peripheral vascular disease, hypertension, dyslipidemia, heart failure, and current smoking), systolic blood pressure (SBP) at admission, hospital size, region, teaching status, and the number of annual stroke discharges from each hospital.

Discussion
==========

In this large, contemporary nationwide study, we observed that 1 of every 3 hospitalized ischemic stroke patients had CKD, that the odds of dying in the hospital after adjusting for major confounders was 44% higher for those patients with CKD compared with those without CKD, and the independent relation of kidney dysfunction with in‐hospital mortality rose progressively with worsening renal dysfunction. These results, based on \>600 000 ischemic stroke admissions at \>1500 hospitals, definitively confirm data from previously published analyses of small single‐center studies that showed a high prevalence of CKD linked to poorer outcomes among hospitalized ischemic stroke patients. In addition, our study is the first as far as we are aware to evaluate the quality of stroke‐related care among hospitalized ischemic stroke patients by CKD presence and stage of kidney dysfunction, finding that patients with evidence of renal dysfunction are significantly less likely to receive several effective therapies, which are currently included in ischemic stroke hospitalization performance and quality measures. This latter finding is in accord with studies among patients hospitalized with acute cardiovascular conditions that revealed greater underuse of medications for vascular risk reduction as kidney function declines.^[@b13]--[@b15]^

A major strength of our study was the ability to also examine the relationships of specific stages of kidney dysfunction to various stroke hospitalization performance measures and in‐hospital outcome types. For instance, while the overriding message from our results is that presence of CKD is associated with lesser compliance with benchmarks of stroke care and poorer outcomes, these results were primarily driven by the more advanced stages of dysfunction, ie, severe and failure. Indeed, hospitalized ischemic stroke patients with mild dysfunction actually had similar or better in‐hospital outcomes when compared with those patients with normal function. On the surface, this may seem counterintuitive since proposed explanations for why vascular disease patients with CKD may have poorer clinical outcomes than those without CKD, is the frequent co‐presence in the former patient group of deleterious conditions like anemia, oxidative stress, electrolyte imbalances, hyperhomocysteinemia, and chronic inflammation.^[@b16]^ However, in our study we observed that patients with mild dysfunction versus normal function were significantly more likely to receive an antithrombotic prescription within 48 hours of admission, be discharged on an antithrombotic, receive anticoagulation at discharge if they had a diagnosis of atrial fibrillation or flutter; showed a strong trend towards being more likely to receive intravenous thrombolysis; showed a non‐significant pattern of being more likely to receive a lipid‐lowering agent at discharge; and were no less likely to receive smoking cessation counseling at discharge, deep venous thrombosis prophylaxis, or overall stroke hospitalization defect‐free care. Although given the nature of our study, we could not establish causality, it is not inconceivable that better in‐hospital care and perhaps significantly higher frequency of pre‐morbid cardiovascular medications in patients with mild CKD versus normal function may have led to similar or better outcomes among the former patient group.

Underutilization of evidence‐based treatments has similarly been seen in other patient subgroups with chronic conditions that place them at high vascular risk such as diabetes mellitus and peripheral artery disease.^[@b17]--[@b18]^ While the specific reasons for why there is an underuse of evidence‐based therapies among hospitalized ischemic patients with CKD are not exactly known, it stands to reason that potential contributors to this evidence‐practice treatment gap may include the facts that the randomized trial evidence upon which several expert‐consensus recommendations for stroke treatment are based typically excluded patients with major renal dysfunction,^[@b9]--[@b10]^ patients with CKD are generally more likely to experience adverse effects of many medications,^[@b19]^ given the effect of renal azotemia on platelet function patients with kidney disease are at an increased risk for bleeding,^[@b20]^ and questionable therapeutic efficacy.^[@b21]--[@b22]^ All of the aforementioned factors may be leading clinicians caring for hospitalized ischemic stroke patients to be more cautious about prescribing these therapies, despite the greater risk for cardiovascular events and poor clinical outcomes in these patients.^[@b2]--[@b6]^ However, emerging evidence suggests that the benefits of many secondary prevention drugs used in the treatment of known vascular disease may be of equal or greater benefit to those with renal dysfunction when compared with those without,^[@b19]^ and a published analysis of the GWTG‐Stroke dataset that looked at predictors of tPA‐related sICH did not find any association between serum creatinine levels and risk for tPA‐related sICH.^[@b23]^

This study has limitations. First, data were derived from the medical record and depended on the accuracy and completeness of clinical documentation (eg, it is conceivable that some patients reported to be eligible for treatment were not treated due to contraindications or intolerance that was not documented; or very ill patients with advanced CKD in the process of being discharged to hospice for terminal care were not candidates for certain treatments). Second, although hospitals are instructed to include all consecutive admissions or to take a random sample, these processes are not audited so the potential for selection bias exists. Third, while we controlled for known confounders, unmeasured confounding could have affected our results. Fourth, our findings may not necessarily apply to hospitals that differ in patient characteristics or care patterns from GWTG‐Stroke hospitals. Fifth, we only examined in‐hospital outcomes, therefore, the longer‐term impact of CKD or of the differences in quality of care identified in this study on stroke‐related outcomes were not determined. Next, although the MDRD formula is the preferred method for estimating renal function, it generally should be applied when renal function is stable, and this may not be the case for many patients admitted with acute ischemic stroke, potentially limiting its usefulness in this population. However, our intent was not to determine precise renal function but to estimate the degree of renal impairment in a large cohort of patients hospitalized with acute ischemic stroke. In addition, admission creatinine was not available in all patients, which may have introduced bias into the findings. Finally, we were unable to definitively establish an association between hospital care performance measures and outcomes or pinpoint the mechanisms by which renal dysfunction may affect mortality.

In conclusion, in this sizeable multi‐site study we confirmed that renal dysfunction prevalence is high and associated with poor clinical outcomes among patients hospitalized with an ischemic stroke. Furthermore, we found that despite higher rates of in‐hospital mortality linked to worsening renal dysfunction, ischemic stroke patients with advanced stages of dysfunction were significantly less likely to receive evidence‐based pharmacologic and non‐pharmacologic management strategies during their index hospitalization. Intensified quality improvement efforts are warranted to enhance the care of hospitalized patients with ischemic stroke and kidney dysfunction.
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